Entering text into the input field will update the search result below

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q1 2021 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2021 Earnings Conference Call May 5, 2021 8:45 AM ET

Company Participants

Pam Murphy - Investor Relations

Bill Collier - President & Chief Executive Officer

Dave Hastings - Chief Financial Officer

Gaston Picchio - Chief Development Officer

Mike Sofia - Chief Scientific Officer

Conference Call Participants

Ed Arce - H.C. Wainwright

Kelechi Chikere - Jefferies

Brian Skorney - Baird

Roy Buchanan - JMP Securities

Mayank Mamtani - B. Riley Securities


Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation 2021 First Quarter Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]

I would now like to hand the conference to your speaker host today, Pam Murphy. Please go ahead.

Pam Murphy

Thank you, and good morning. On the call from Arbutus executive team are, Bill Collier, President and Chief Executive Officer; Dave Hastings, Chief Financial Officer; Dr. Gaston Picchio, Chief Development Officer; and Dr. Mike Sofia, Chief Scientific Officer.

Bill will begin with the review of the first quarter's accomplishment, clinical development and remaining 2021 corporate objectives; followed by Dave Hastings, who will provide a the review of the company's first quarter financial results. We'll then open up the call for Q&A. Mike and Gaston will be available to address any research and clinical development related questions.

Before we begin, we'd like to remind you, that some of the statements made during the call today, are forward-looking statements, including statements regarding expectations for Arbutus' proprietary HBV pipeline and pan-coronavirus discovery program, including potential clinical results and timelines for AB-729 and AB-836 and any future compound; our expected cash used and cash runway and the

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.